MCL1 and amyloidosis: For patients with advanced disease that may not be able to tolerate bortezomib treatment at diagnosis due to excessive disease-induced organ dysfunction, use of an MCL-1 inhibitor as a single agent may be effective at eliminating those cells that would typically be sensitive to bortezomib while being less toxic to healthy tissues affected by amyloid deposition.